Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Conference News AHA 2020

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

Michael O'Riordan

November 14, 2020

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

Presentation AHA 2018

DECLARE - TIMI 58

Presenter: Stephen Wiviott

November 11, 2018

News Conference News AHA 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

Todd Neale

November 10, 2018

News Daily News

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

Michael O'Riordan

May 21, 2018

Presentation TCT 2015

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Giora Weisz

October 13, 2015

Presentation TCT 2015

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

Presenter: Bernard J. Gersh, Stephen D. Wiviott

October 13, 2015

Presentation TCT 2015

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Evan A. Stein

October 13, 2015

Presentation TCT 2015

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Presenter: Bernard J. Gersh, Stephen D. Wiviott, David J. Maron

October 13, 2015

Presentation TCT 2015

Does PEGASUS Inform the Debate?

Presenter: John A. Bittl, Gary L. Schaer, Stephen D. Wiviott

October 12, 2015

News Daily News

Prasugrel Efficacy in STEMI Largely Unaffected by PCI Timing

Yael L. Maxwell

June 17, 2014

News Daily News

TRILOGY ACS Substudy: Prasugrel Post-Angiography Minimizes Risk of Adverse Events

Yael L. Maxwell

August 23, 2013

News Daily News

Subestudio del TRILOGY ACS: El Prasugrel Post-Angiografía Minimiza el Riesgo de Episodios Adversos

Yael L. Maxwell

August 23, 2013

Presentation

Prasugrel vs. Clopidogrel for Patients with Unstable Angina or NSTEMI With or Without Angiography

Presenter: Stephen D. Wiviott

August 20, 2013

News Conference News TCT 2012

TRILOGY ACS Substudy: Angiography Prior to Prasugrel Therapy Reduces CV Events

October 25, 2012

Presentation TCT 2012

TRILOGY ACS Angiographic Cohort: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After...

Presenter: Stephen Wiviott

October 24, 2012

News Industry News

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

October 24, 2012

News Daily News

High Platelet Reactivity Predicts Poor Outcomes, Routine Testing Still Debated

Jason Kahn

October 24, 2011

Advertisement

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

DECLARE - TIMI 58

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Does PEGASUS Inform the Debate?

Prasugrel Efficacy in STEMI Largely Unaffected by PCI Timing

TRILOGY ACS Substudy: Prasugrel Post-Angiography Minimizes Risk of Adverse Events

Subestudio del TRILOGY ACS: El Prasugrel Post-Angiografía Minimiza el Riesgo de Episodios Adversos

Prasugrel vs. Clopidogrel for Patients with Unstable Angina or NSTEMI With or Without Angiography

TRILOGY ACS Substudy: Angiography Prior to Prasugrel Therapy Reduces CV Events

TRILOGY ACS Angiographic Cohort: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After...

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

High Platelet Reactivity Predicts Poor Outcomes, Routine Testing Still Debated

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content